These results suggest that IL-6 reflects both persistent systemic inflammation and visceral fat dysfunction, contributing to heightened cardiovascular risk and supporting its role as a clinically informative biomarker in well-treated psoriasis. This evidence concerns the gene IL6 and psoriasis.